Tubulis closed a €308 million (about $356 million) Series C to accelerate clinical development of its antibody‑drug conjugate portfolio, led by lead candidate TUB‑040. The round is among the largest European biopharma financings this year and is earmarked to expand indications and move programs into earlier lines of therapy. The financing positions Tubulis to present and advance clinical data at major oncology meetings while scaling manufacturing and broader pipeline work.